|
End-of-day quote
Taiwan S.E.
2026-08-17
|
5-day change | 1st Jan Change | ||
| 48.70 TWD | -5.44% |
|
-3.94% | -21.07% |
| 07-13 | EirGenix Partner Secures EMA Nod for Breast Cancer Biosimilar Vial | MT |
| 05-26 | Transcenta Secures 7 Million Yuan Milestone Payment Under EirGenix Bio-Platform Deal; Shares Fall 7% | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- 6589 Stock
- Consensus EirGenix Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
